FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386417512> ?p ?o ?g. }

• W4386417512 abstract "Introduction Immune correlates of protection afforded by PHV02, a recombinant vesicular stomatitis (rVSV) vector vaccine against Nipah virus (NiV) disease, were investigated in the African green monkey (AGM) model. Neutralizing antibody to NiV has been proposed as the principal mediator of protection against future NiV infection. Methods Two approaches were used to determine the correlation between neutralizing antibody levels and outcomes following a severe (1,000 median lethal doses) intranasal/intratracheal (IN/IT) challenge with NiV (Bangladesh): (1) reduction in vaccine dose given 28 days before challenge and (2) challenge during the early phase of the antibody response to the vaccine. Results Reduction in vaccine dose to very low levels led to primary vaccine failure rather than a sub-protective level of antibody. All AGMs vaccinated with the nominal clinical dose (2 × 10 7 pfu) at 21, 14, or 7 days before challenge survived. AGMs vaccinated at 21 days before challenge had neutralizing antibodies (geometric mean titer, 71.3). AGMs vaccinated at 7 or 14 days before challenge had either undetectable or low neutralizing antibody titers pre-challenge but had a rapid rise in titers after challenge that abrogated the NiV infection. A simple logistic regression model of the combined studies was used, in which the sole explanatory variable was pre-challenge neutralizing antibody titers. For a pre-challenge titer of 1:5, the predicted survival probability is 100%. The majority of animals with pre-challenge neutralizing titer of ≥1:20 were protected against pulmonary infiltrates on thoracic radiograms, and a majority of those with titers ≥1:40 were protected against clinical signs of illness and against a ≥fourfold antibody increase following challenge (indicating sterile immunity). Controls receiving rVSV-Ebola vaccine rapidly succumbed to NiV challenge, eliminating the innate immunity stimulated by the rVSV vector as a contributor to survival in monkeys challenged as early as 7 days after vaccination. Discussion and conclusion It was concluded that PHV02 vaccine elicited a rapid onset of protection and that any detectable level of neutralizing antibody was a functional immune correlate of survival." @default.
• W4386417512 created "2023-09-05" @default.
• W4386417512 creator A5002762511 @default.
• W4386417512 creator A5004256871 @default.
• W4386417512 creator A5005214765 @default.
• W4386417512 creator A5010231261 @default.
• W4386417512 creator A5023332141 @default.
• W4386417512 creator A5024448762 @default.
• W4386417512 creator A5028450611 @default.
• W4386417512 creator A5033948607 @default.
• W4386417512 creator A5044498245 @default.
• W4386417512 creator A5044863582 @default.
• W4386417512 creator A5055066987 @default.
• W4386417512 creator A5060206727 @default.
• W4386417512 creator A5061916366 @default.
• W4386417512 creator A5087518648 @default.
• W4386417512 date "2023-09-04" @default.
• W4386417512 modified "2023-09-28" @default.
• W4386417512 title "Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease" @default.
• W4386417512 cites W1486170959 @default.
• W4386417512 cites W1655759188 @default.
• W4386417512 cites W1973689128 @default.
• W4386417512 cites W1992275074 @default.
• W4386417512 cites W2032294909 @default.
• W4386417512 cites W2059658426 @default.
• W4386417512 cites W2069131737 @default.
• W4386417512 cites W2088173462 @default.
• W4386417512 cites W2133392162 @default.
• W4386417512 cites W2154293331 @default.
• W4386417512 cites W2169315144 @default.
• W4386417512 cites W2483119975 @default.
• W4386417512 cites W2485893359 @default.
• W4386417512 cites W2502823729 @default.
• W4386417512 cites W2564361602 @default.
• W4386417512 cites W2604427881 @default.
• W4386417512 cites W2606044283 @default.
• W4386417512 cites W2624564619 @default.
• W4386417512 cites W2911486836 @default.
• W4386417512 cites W2917626770 @default.
• W4386417512 cites W2963998586 @default.
• W4386417512 cites W2977314956 @default.
• W4386417512 cites W2994899803 @default.
• W4386417512 cites W3004874410 @default.
• W4386417512 cites W3034103987 @default.
• W4386417512 cites W3111029871 @default.
• W4386417512 cites W3112632192 @default.
• W4386417512 cites W3157530174 @default.
• W4386417512 cites W3163785571 @default.
• W4386417512 cites W3198178314 @default.
• W4386417512 cites W3209339997 @default.
• W4386417512 cites W35530500 @default.
• W4386417512 cites W4281745146 @default.
• W4386417512 cites W4283590984 @default.
• W4386417512 doi "https://doi.org/10.3389/fimmu.2023.1216225" @default.
• W4386417512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37731485" @default.
• W4386417512 hasPublicationYear "2023" @default.
• W4386417512 type Work @default.
• W4386417512 citedByCount "0" @default.
• W4386417512 crossrefType "journal-article" @default.
• W4386417512 hasAuthorship W4386417512A5002762511 @default.
• W4386417512 hasAuthorship W4386417512A5004256871 @default.
• W4386417512 hasAuthorship W4386417512A5005214765 @default.
• W4386417512 hasAuthorship W4386417512A5010231261 @default.
• W4386417512 hasAuthorship W4386417512A5023332141 @default.
• W4386417512 hasAuthorship W4386417512A5024448762 @default.
• W4386417512 hasAuthorship W4386417512A5028450611 @default.
• W4386417512 hasAuthorship W4386417512A5033948607 @default.
• W4386417512 hasAuthorship W4386417512A5044498245 @default.
• W4386417512 hasAuthorship W4386417512A5044863582 @default.
• W4386417512 hasAuthorship W4386417512A5055066987 @default.
• W4386417512 hasAuthorship W4386417512A5060206727 @default.
• W4386417512 hasAuthorship W4386417512A5061916366 @default.
• W4386417512 hasAuthorship W4386417512A5087518648 @default.
• W4386417512 hasBestOaLocation W43864175121 @default.
• W4386417512 hasConcept C159047783 @default.
• W4386417512 hasConcept C159654299 @default.
• W4386417512 hasConcept C203014093 @default.
• W4386417512 hasConcept C22070199 @default.
• W4386417512 hasConcept C22889606 @default.
• W4386417512 hasConcept C2522874641 @default.
• W4386417512 hasConcept C2779057330 @default.
• W4386417512 hasConcept C2779261636 @default.
• W4386417512 hasConcept C32611913 @default.
• W4386417512 hasConcept C71924100 @default.
• W4386417512 hasConceptScore W4386417512C159047783 @default.
• W4386417512 hasConceptScore W4386417512C159654299 @default.
• W4386417512 hasConceptScore W4386417512C203014093 @default.
• W4386417512 hasConceptScore W4386417512C22070199 @default.
• W4386417512 hasConceptScore W4386417512C22889606 @default.
• W4386417512 hasConceptScore W4386417512C2522874641 @default.
• W4386417512 hasConceptScore W4386417512C2779057330 @default.
• W4386417512 hasConceptScore W4386417512C2779261636 @default.
• W4386417512 hasConceptScore W4386417512C32611913 @default.
• W4386417512 hasConceptScore W4386417512C71924100 @default.
• W4386417512 hasLocation W43864175121 @default.
• W4386417512 hasLocation W43864175122 @default.
• W4386417512 hasOpenAccess W4386417512 @default.
• W4386417512 hasPrimaryLocation W43864175121 @default.
• W4386417512 hasRelatedWork W1678510290 @default.
• W4386417512 hasRelatedWork W1972745941 @default.

• next